Advanced search
Publication Cover
Pharmacogenomics Volume 14, 2013 - Issue 10
Submit an article Journal homepage
325
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Pharmacodynamic Genetic Variants Related to Antipsychotic Adverse Reactions in Healthy Volunteers

Rosario López-Rodríguez1 Liver Unit, Gastroenterology Service, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-IP), Diego de Leon 62, 3ª, 28006Madrid, Spain.;2 Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, SpainCorrespondence[email protected]
View further author information
,
Teresa Cabaleiro3 Service of Clinical Pharmacology, Hospital Universitario de La Princesa, Instituto Teófilo Hernando, Instituto de Investigación Sanitaria Princesa (IIS-IP), Madrid, SpainView further author information
,
Dolores Ochoa3 Service of Clinical Pharmacology, Hospital Universitario de La Princesa, Instituto Teófilo Hernando, Instituto de Investigación Sanitaria Princesa (IIS-IP), Madrid, SpainView further author information
,
Manuel Román3 Service of Clinical Pharmacology, Hospital Universitario de La Princesa, Instituto Teófilo Hernando, Instituto de Investigación Sanitaria Princesa (IIS-IP), Madrid, SpainView further author information
,
Alberto M Borobia4 Service of Clinical Pharmacology, Hospital Universitario La Paz, Pharmacology Department, School of Medicine, Universidad Autónoma de Madrid, Madrid, SpainView further author information
,
Antonio J Carcas4 Service of Clinical Pharmacology, Hospital Universitario La Paz, Pharmacology Department, School of Medicine, Universidad Autónoma de Madrid, Madrid, SpainView further author information
,
Carmen Ayuso5 Department of Genetics & Genomics, Instituto de Investigación Sanitaria Fundacion Jimenez Diaz, Madrid, Spain;6 Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, Madrid, SpainView further author information
,
Jesús Novalbos3 Service of Clinical Pharmacology, Hospital Universitario de La Princesa, Instituto Teófilo Hernando, Instituto de Investigación Sanitaria Princesa (IIS-IP), Madrid, SpainView further author information
&
Francisco Abad-Santos2 Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain;3 Service of Clinical Pharmacology, Hospital Universitario de La Princesa, Instituto Teófilo Hernando, Instituto de Investigación Sanitaria Princesa (IIS-IP), Madrid, SpainView further author information
 show all
Pages 1203-1214 | Published online: 16 Jul 2013

References

  • Kane JM . Addressing nonresponse in schizophrenia. J. Clin. Psychiatry73(2), e07 (2012).
  • Lieberman JA , StroupTS, McEvoyJP et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 353(12), 1209–1223 (2005).
  • Tarsy D , BaldessariniRJ, TaraziFI. Effects of newer antipsychotics on extrapyramidal function. CNS Drugs16(1), 23–45 (2002).
  • Zhong KX , SweitzerDE, HamerRM, LiebermanJA. Comparison of quetiapine and risperidone in the treatment of schizophrenia: a randomized, double-blind, flexible-dose, 8-week study. J. Clin. Psychiatry67(7), 1093–1103 (2006).
  • Maher AR , MaglioneM, BagleyS et al. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. JAMA 306(12), 1359–1369 (2011).
  • Arranz MJ , de Leon J. Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. Mol. Psychiatry12(8), 707–747 (2007).
  • Evans WE , McLeodHL. Pharmacogenomics – drug disposition, drug targets, and side effects. N. Engl. J. Med.348(6), 538–549 (2003).
  • Wilke RA , DolanME. Genetics and variable drug response. JAMA306(3), 306–307 (2011).
  • Arranz MJ , RiveraM, MunroJC. Pharmacogenetics of response to antipsychotics in patients with schizophrenia. CNS Drugs25(11), 933–969 (2011).
  • Ryu S , OhS, ChoEY et al. Interaction between genetic variants of DLGAP3 and SLC1A1 affecting the risk of atypical antipsychotics-induced obsessive-compulsive symptoms. Am. J. Med. Genet. B. Neuropsychiatr. Genet. 156B(8), 949–959 (2011).
  • Lopez-Rodriguez R , RomanM, NovalbosJ, PelegrinaML, OchoaD, Abad-SantosF. DRD2 Taq1A polymorphism modulates prolactin secretion induced by atypical antipsychotics in healthy volunteers. J. Clin. Psychopharmacol.31(5), 555–562 (2011).
  • Novalbos J , Lopez-RodriguezR, RomanM, Gallego-SandinS, OchoaD, Abad-SantosF. Effects of CYP2D6 genotype on the pharmacokinetics, pharmacodynamics, and safety of risperidone in healthy volunteers. J. Clin. Psychopharmacol.30(5), 504–511 (2010).
  • Penas-LLedo EM , DoradoP, PachecoR, GonzalezI, LLerenaA. Relation between CYP2D6 genotype, personality, neurocognition and overall psychopathology in healthy volunteers. Pharmacogenomics10(7), 1111–1120 (2009).
  • Gonzalez I , Penas-LledoEM, PerezB, DoradoP, AlvarezM, LLerenaA. Relation between CYP2D6 phenotype and genotype and personality in healthy volunteers. Pharmacogenomics9(7), 833–840 (2008).
  • Karch FE , LasagnaL. Toward the operational identification of adverse drug reactions. Clin. Pharmacol. Ther.21(3), 247–254 (1977).
  • Bozina N , KuzmanMR, MedvedV, JovanovicN, SerticJ, HotujacL. Associations between MDR1 gene polymorphisms and schizophrenia and therapeutic response to olanzapine in female schizophrenic patients. J. Psychiatr. Res.42(2), 89–97 (2008).
  • Kocabas NA . Catechol-O-methyltransferase (COMT) pharmacogenetics in the treatment response phenotypes of major depressive disorder (MDD). CNS Neurol. Disord. Drug Targets11(3), 264–272 (2012).
  • Kuzman MR , MedvedV, BozinaN, GrubisinJ, JovanovicN, SerticJ. Association study of MDR1 and 5-HT2C genetic polymorphisms and antipsychotic-induced metabolic disturbances in female patients with schizophrenia. Pharmacogenomics J.11(1), 35–44 (2010).
  • Lesch KP , GutknechtL. Pharmacogenetics of the serotonin transporter. Prog. Neuropsychopharmacol. Biol. Psychiatry29(6), 1062–1073 (2005).
  • Allen NC , BagadeS, McQueenMB et al. Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. Nat. Genet. 40(7), 827–834 (2008).
  • Aragam N , WangKS, AndersonJL, LiuX. TMPRSS9 and GRIN2B are associated with neuroticism: a genome-wide association study in a European sample. J. Mol. Neurosci.50(2), 250–256 (2012).
  • Almoguera B , Riveiro-AlvarezR, Gomez-DominguezB et al. Evaluating a newly developed pharmacogenetic array: screening in a Spanish population. Pharmacogenomics 11(11), 1619–1625 (2010).
  • Haddad PM , SharmaSG. Adverse effects of atypical antipsychotics: differential risk and clinical implications. CNS Drugs21(11), 911–936 (2007).
  • Komossa K , Rummel-KlugeC, SchwarzS et al. Risperidone versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst. Rev. (1), CD006626 (2011).
  • Deng C , LianJ, PaiN, HuangXF. Reducing olanzapine-induced weight gain side effect by using betahistine: a study in the rat model. J. Psychopharmacol.26(9), 1271–1279 (2012).
  • Deng C , Weston-GreenK, HuangXF. The role of histaminergic H1 and H3 receptors in food intake: a mechanism for atypical antipsychotic-induced weight gain? Prog. Neuropsychopharmacol. Biol. Psychiatry34(1), 1–4 (2010).
  • Jarskog LF , MiyamotoS, LiebermanJA. Schizophrenia: new pathological insights and therapies. Annu. Rev. Med.58, 49–61 (2007).
  • Kroeze WK , HufeisenSJ, PopadakBA et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 28(3), 519–526 (2003).
  • Houston JP , KohlerJ, BishopJR et al. Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia. J. Clin. Psychiatry 73(8), 1077–1086 (2012).
  • Boonleang J , PipatrattanasereeW, TanthanaC, MahatthanatrakulW. Relative bioavailability and pharmacokinetic comparison of two 2-mg risperidone tablet formulations: a single dose, randomized-sequence, double-blind, 2-way crossover study in healthy male volunteers in Thailand. Clin. Ther.32(10), 1842–1853 (2011).
  • Markowitz JS , DevaneCL, BoultonDW, ListonHL, RischSC. Hypotension and bradycardia in a healthy volunteer following a single 5 mg dose of olanzapine. J. Clin. Pharmacol.42(1), 104–106 (2002).
  • Sathirakul K , ChanC, TengL, BergstromRF, YeoKP, WiseSD. Olanzapine pharmacokinetics are similar in Chinese and Caucasian subjects. Br. J. Clin. Pharmacol.56(2), 184–187 (2003).
  • Seeman MV . Secondary effects of antipsychotics: women at greater risk than men. Schizophr. Bull.35(5), 937–948 (2009).
  • Hedenmalm K , GuzeyC, DahlML, YueQY, SpigsetO. Risk factors for extrapyramidal symptoms during treatment with selective serotonin reuptake inhibitors, including cytochrome P-450 enzyme, and serotonin and dopamine transporter and receptor polymorphisms. J. Clin. Psychopharmacol.26(2), 192–197 (2006).
  • Koning JP , VehofJ, BurgerH et al. Association of two DRD2 gene polymorphisms with acute and tardive antipsychotic-induced movement disorders in young Caucasian patients. Psychopharmacology (Berl.) 219(3), 727–736 (2011).
  • Bakker PR , van Harten PN, van Os J. Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions. Mol. Psychiatry13(5), 544–556 (2008).
  • Chen CH , WeiFC, KoongFJ, HsiaoKJ. Association of TaqI A polymorphism of dopamine D2 receptor gene and tardive dyskinesia in schizophrenia. Biol. Psychiatry41(7), 827–829 (1997).
  • Zai CC , De Luca V, Hwang RW et al. Meta-analysis of two dopamine D2 receptor gene polymorphisms with tardive dyskinesia in schizophrenia patients. Mol. Psychiatry12(9), 794–795 (2007).
  • Yasui-Furukori N , SaitoM, TsuchimineS et al. Association between dopamine-related polymorphisms and plasma concentrations of prolactin during risperidone treatment in schizophrenic patients. Prog. Neuropsychopharmacol. Biol. Psychiatry 32(6), 1491–1495 (2008).
  • Young RM , LawfordBR, BarnesM et al. Prolactin levels in antipsychotic treatment of patients with schizophrenia carrying the DRD2*A1 allele. Br. J. Psychiatry 185, 147–151 (2004).
  • Thompson J , ThomasN, SingletonA et al. D2 dopamine receptor gene (DRD2) Taq1 A polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele. Pharmacogenetics 7(6), 479–484 (1997).
  • Dolzan V , PlesnicarBK, SerrettiA et al. Polymorphisms in dopamine receptor DRD1 and DRD2 genes and psychopathological and extrapyramidal symptoms in patients on long-term antipsychotic treatment. Am. J. Med. Genet. B. Neuropsychiatr. Genet. 144B(6), 809–815 (2007).
  • Murphy GM Jr, Hollander SB, Rodrigues HE, Kremer C, Schatzberg AF. Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression. Arch. Gen. Psychiatry61(11), 1163–1169 (2004).
  • Perlis RH , MischoulonD, SmollerJW et al. Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment. Biol. Psychiatry 54(9), 879–883 (2003).
  • Biernacka JM , McElroySL, CrowS et al. Pharmacogenomics of antidepressant induced mania: a review and meta-analysis of the serotonin transporter gene (5HTTLPR) association. J. Affect. Disord. 136(1–2), e21–e29 (2011).
  • Lesch KP , BengelD, HeilsA et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 274(5292), 1527–1531 (1996).
  • Mortensen OV , ThomassenM, LarsenMB, WhittemoreSR, WiborgO. Functional analysis of a novel human serotonin transporter gene promoter in immortalized raphe cells. Brain Res. Mol. Brain Res.68(1–2), 141–148 (1999).
  • Hu XZ , RushAJ, CharneyD et al. Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression. Arch. Gen. Psychiatry 64(7), 783–792 (2007).
  • Zalsman G , HuangYY, OquendoMA et al. Association of a triallelic serotonin transporter gene promoter region (5-HTTLPR) polymorphism with stressful life events and severity of depression. Am. J. Psychiatry 163(9), 1588–1593 (2006).
  • Hong CJ , YuYW, LinCH, ChengCY, TsaiSJ. Association analysis for NMDA receptor subunit 2B (GRIN2B) genetic variants and psychopathology and clozapine response in schizophrenia. Psychiatr. Genet.11(4), 219–222 (2001).
  • Cabaleiro T , Lopez-RodriguezR, OchoaD, RomanM, NovalbosJ, Abad-SantosF. Polymorphisms influencing olanzapine metabolism and adverse effects in healthy subjects. Hum. Psychopharmacol.28(3), 205–214 (2013).
  • Holden M , DengS, WojnowskiL, KulleB. GSEA-SNP: applying gene set enrichment analysis to SNP data from genome-wide association studies. Bioinformatics24(23), 2784–2785 (2008).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.